Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an ...
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
pharmaphorum1y
Sanofi will exit consumer health and boost R&D investment
In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...
policymed.com10d
Sanofi Sues HHS Over 340B Changes
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...
FiercePharma24d
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
stomach cramp reliever Buscopan and pain treatments Icy Hot and Gold Bond, among others. While Opella has long operated as a standalone unit within Sanofi, boasting more than 11,000 employees ...
Sanofi in exclusive talks with CD&R over sale of $17 bn Opella
Allegra allergy treatments and Buscopan pain relief. Sanofi, which said a year ago it was reviewing separation scenarios for ...
Sanofi Plans Share Buybacks, Signals More Deals Post Opella Sale
The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...